Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg (Blend)

Key points

• The blend combines tesamorelin and CJC-1295 without DAC (both GHRH analogues) with ipamorelin.
• Together they are meant to produce a strong pulse of growth hormone.
• None of the components is licensed in the UK, and combining them does not change that.
• All are on the WADA Prohibited List.

Quick facts

What it is

Blend of tesamorelin, CJC-1295 (no DAC) and ipamorelin

Marketed for

Growth hormone support

UK status

Not a licensed medicine; sold for research use

In sport

All components prohibited

How it works

The two GHRH analogues and the ghrelin receptor peptide act through complementary routes, aiming for a larger growth hormone pulse than any alone. See the tesamorelin, CJC-1295 and ipamorelin entries for detail.

What the evidence shows

There is no evidence for this blend as a specific product. The components have their own evidence individually, and there are no controlled trials of this three way combination.

What it does not settle

• There are no controlled trials of this blend.
• The exact contents and ratios of a given vial are uncertain.
• Long term safety of the combination is unknown.

Side effects

Less common but serious

• The risks are those of the individual components, including effects on glucose and fluid balance from stronger growth hormone stimulation.
• Because there is no licensed product, the dose, purity and contents of material bought online cannot be verified.

Report any suspected side effect through the MHRA Yellow Card scheme.

UK legal status and access

This blend has no UK marketing authorisation, so it is not a licensed medicine and is not offered by registered clinics or pharmacies. It is sold online for research use.

Common questions